x min read

4 Penny Stocks to Put on Your Radar: GAXY GRTX ONPH SEAC

4 Penny Stocks to Put on Your Radar: GAXY GRTX ONPH SEAC
Published on
December 23, 2021
Copy URL
Share on LinkedIn
Share on Reddit
Share on Twitter/X
Share on Facebook

There are plenty of opportunities for investors if they follow us here at Insider Financial.The key to trading stocks is finding the momentum BEFORE it happens and then being patient. Now, when we say that we find momentum BEFORE it happens, we are investors looking to position our subscribers BEFORE the move happens.It’s also best to own a portfolio of penny stocks. For some that can be as many as 10 to 20 or more stocks that include both OTC stocks and NASDAQ stocks. We don't necessarily stick to OTC tickers since NASDAQ-listed penny stocks can also generate impressive returns.We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.[embed]https://www.youtube.com/watch?v=9cP3aiNcuSc[/embed]The fact is that there is always a bull market somewhere. That’s why it’s important for investors to trade both OTC and NASDAQ stocks, and sometimes get exposure to larger companies that still seem to have massive growth potential. There are always opportunities if you give yourself the flexibility to trade all markets.In this article, we take a look at 4 penny stocks worth watching right now, two of which are listed on NASDAQ. They are Galaxy Next Generation, Inc (OTCQB: GAXY), Galera Therapeutics, Inc (NASDAQ: GRTX), Oncology Pharma Inc (OTCPK: ONPH), and SeaChange International, Inc (NASDAQ: SEAC). Penny stocks #1 GAXY Penny stocks #2 GRTX Penny stocks #3 ONPH Penny stocks #4 SEAC


Galaxy Next Generation, Inc has bounced back from the lowest level of the year touched at the beginning of December. The OTCQB stock is ready to consolidate above the one penny mark, currently trading at $0.011, up almost 60% during the last five trading sessions.GAXY manufactures and distributes interactive learning technologies and enhanced audio solutions. It develops both hardware and software that allows presenters and participants to engage in a fully collaborative instructional environment. It also develops award-winning classroom audio solutions and school PA and Intercom products, creating a full line card offering for classrooms to its channel partners.The products include the company’s proprietary private-label interactive touch screen panel as well as numerous other national and international branded peripheral and communication devices. GAXY’s technologies, such as touchscreen panels, are sold along with renowned brands such as Google Chromebooks, Microsoft Surface Tablets, Lenovo and Acer computers, Verizon WiFi, and more.Besides production, GAXY’s services include installation, training, and maintenance. The company’s current distribution channel consists of 30 resellers across the US, which sell for the commercial and educational market.Last month, the company reported the highest quarterly revenue on record, with sales going up by 43% to almost $1.7 million. The net loss was significantly reduced to $0.4 million from $13.1 million year-on-year, while total assets went up to $7 million. Despite the upbeat report, the OTC stock couldn’t withstand the bearish pressure.Bulls took control on December 7, when the company said that it had extinguished the equity line of credit (ELOC) that had been established at the beginning of 2021. The ELOC was needed to help the company with growth and financial stability. Over the past 11 months, GAXY has issued shares under its effective S-1 to institutional investors in exchange for cash, enabling it to achieve several goals, such as reducing liabilities from $13.3 million as of December 31, 2020, to $7.8 million.Besides ending the ELOC, GAXY announced on Tuesday that it had bought back 50 million shares and retired them to Treasury, with the total shares outstanding being reduced from 3.43 billion to 3.38 billion.All in all, the share structure is improving along with the financials, so GAXY is ready to make new highs.https://twitter.com/cooltigerx/status/1472769317477494784


Galera Therapeutics, Inc has surged by over 200% over the month, taking many investors by surprise after touching a record low earlier in December when it fell below $1.3. Now you can buy the NASDAQ-listed stock for $4.41.The clinical-stage biopharmaceutical company focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The lead product candidate is Avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is currently tested in the following trials:

  • Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC);
  • Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer;
  • Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy;
  • It has completed a pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease.

https://www.galeratx.com/our-pipeline/gc4419/The company is also developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer.In October, GRTX’s share price tumbled from over $8 to less than $2 after the release of a series of results related to its lead product Avasopasem manganese. Specifically, the company said that the results of its Phase 3 ROMAN study covering the treatment of “RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC)” hadn’t achieved statistical significance. Last week, GRTX released the corrected results of the same trial, which actually showed a better outcome than expected. It seems that the results were initially wrong due to an error by a contract research organization.Mel Sorensen, M.D., President and CEO of Galera, said:

“Given the high unmet medical need for patients with head and neck cancer who develop radiotherapy-induced severe oral mucositis, we are gratified that the Phase 3 ROMAN trial achieved statistical significance on the primary endpoint after the correction of the statistical programming error.”

Now that the results have been corrected, GRTX may attempt to reclaim the $10 level where it was at the beginning of the year, so make sure to keep an eye on this $110+ million company.


Oncology Pharma Inc is another stock that is recovering from a recent multi-month low.Our subscribers and readers may be familiar with ONPH from our posts that mention Regen BioPharma (OTCMKTS: RGBP), a great OTC stock with long-term potential. RGBP signed two deals with Oncology – one deal focuses on treating pancreatic cancer, and the other one is between Regen’s subsidiary KCL Therapeutics, Inc, and Oncology for the treatment of colon cancer.ONPH is a pioneering oncology company dedicated to licensing, developing, manufacturing and commercializing therapeutics and opportunities within the biopharma space. The company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the field of cancer therapies, epidemiology and leadership to identify and negotiate research, technologies, and drug delivery that are synergistic and collaborative.ONPH is now trading at $6.06, up almost 100% since last week when it touched the lowest level since January at less than $2.90. Even though $6 seems a lot for a Pink Current stock, ONPH peaked at over $43 in February, so there is a long way to fully recover.The share price rebounded after the company announced that it had conducted a meeting with its Board of Directors, executives, and world-class advisors. The team decided to pursue specific technologies, such as the Connect2Med trials program with Ribeira Solutions along with pediatric and orphan drug designations and possible strategies to pursue for a company of its size. Amongst that focus is the nanoemulsion of dactinomycin. ONPH and its partners are currently undertaking the creation and testing of targeted formulations to include in the studies that will be submitted to in-depth trials.The company has developed the framework and is conducting early feasibility and initial non-clinical studies. It is in the process of creating data that focuses on using its dactinomycin nanoemulsion drug product, intended for the treatment of pediatric cancers. Dactinomycin has been shown to be effective in destroying cancer cells. Utilizing the nanoemulsion for the targeted delivery system is expected to allow a safe dose of the drug to be delivered over time, so it may be safely administered. The company anticipates there will be more developments and opportunities to pursue. With early indications confirming initial assumptions, the work so far has been encouraging and proceeding on schedule.Dactinomycin was approved by the FDA more than five decades ago but has been limited in its utility due to severe toxic side effects at effective doses. ONPH believes its novel formulation currently in development can overcome this limitation by creating a safer and potentially more effective drug formulation. This formulation may also enable greater accumulation of the drug at the tumor site, potentially increasing its tumor-kill effectiveness while simultaneously sparing healthy tissues.This will be the first drug application for ONPH, so there may be great opportunities for investors in the following months, especially given that the price has been corrected for a while. ONPH looks like a discount entry opportunity at current levels.


SeaChange International, Inc has been surging lately and hit the highest since April 2020 on expectations of a reverse merger. The NASDAQ-listed stock has jumped over 270% over the month to trade at $2.57 at a market cap of over $140 million.On Wednesday, previous rumors spread by Reuters and Bloomberg were confirmed. SEAC, a company focused on advanced digital advertising, is going through a reverse merger with Triller Hold Co LLC, which counts TikTok among its rivals. The post-merger company is expected to have a valuation of about $5 billion, so it’s time to jump on this stock until it’s not too late. Elsewhere, PitchBook says that the transaction would value Triller at a premium to its most recent valuation of $1.25 billion, which will still put its stock price at dozens of USD.TrillerVerz is working to become a leading Artificial Intelligence-powered social media platform for content, creators and commerce and is going public through the merger. The resulted company will change its name to TrillerVerz Corp, and the new ticker symbol will be ILLR.TrillerVerz expects it will create a leading voice on the Web3.0 movement and embrace the power of decentralized systems to enable greater participation in the multi-hundred billion dollar creator economy. It believes that creators deserve to own, manage, distribute and monetize their content, and TrillerVerz is designed for ever greater creator control, extensibility, and agency.The company’s services enable creators of all kinds (artists, athletes, influencers, public figures, and brands) to engage and build audiences across all open platforms with unique channels of communication they can control. TrillerVerz enables over 750 million interactions with consumers every month.TrillerVerz has a proven track record of producing world-class content around the Triller Fight Club and Verzuzbrands, showcasing artists, athletes, and personalities and building a large, growing, and re-targetable audience of millions of users around the world. The company plans to diversify its revenue streams by expanding its global footprint and investing in new growth opportunities across the creator economy and emerging technologies. The combined company will be well-positioned to pursue a robust acquisition strategy that will only strengthen its economic engine.Triller’s app has been downloaded 250 million times and has counted former US President Donald Trump, Justin Bieber and Alicia Keys among its verified users. It also counts Ryan Kavanaugh and Bobby Sarnevesht as co-controlling shareholders of its parent, TrillerNet.The deal is expected to close in the first quarter of 2022, subject to regulatory and stockholder approvals and the satisfaction of other closing conditions, including specified working capital requirements.Upon closing, the combined company will be led by TrillerVerz’s CEO, Mahi de Silva, who will also become Chairman of the Board. Peter Aquino, President and CEO of SeaChange will join the TrillerVerz team.Mahi de Silva commented:

“We are thrilled to announce this important milestone of TrillerVerz's plans to enter the public market. In our short history, we have evolved from a disruptive social media platform and creator of content to one of the world's most successful platforms where creators, commerce, and culture meet.”

We think this is a rare opportunity to invest in something that can provide guaranteed long-term returns. If the merger takes place in the following months, the share price should skyrocket by at least ten times. Make sure to put SEAC on your radar!https://twitter.com/MYellow28/status/1473627868886360072


Now is a great opportunity to invest in top penny stocks with great potential. Our job is to identify the best penny stocks with strong fundamentals and let our subscribers pick the ones they like to build a well-diversified portfolio.Buying dips and selling rips as swing trades remains the best strategy in the stock market. Still, whenever a hot stock is in the middle of a bull run, we recommend our subscribers to book profits.It’s very important to eye penny stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.Remember, all you need is one or two penny stocks to run in order to crush the market averages.As always, good luck to all (except the shorts)!


Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.

Discover Hidden Gems

Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.